Your browser doesn't support javascript.
loading
Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer.
Pérol, Maurice; Pavlakis, Nick; Levchenko, Evgeny; Platania, Marco; Oliveira, Julio; Novello, Silvia; Chiari, Rita; Moran, Teresa; Mitry, Emmanuel; Nüesch, Eveline; Liu, Ting; Balas, Bogdana; Konopa, Krzysztof; Peters, Solange.
Afiliación
  • Pérol M; Department of Medical Oncology, Léon Bérard Cancer Center, 69008 Lyon, France. Electronic address: maurice.perol@lyon.unicancer.fr.
  • Pavlakis N; Department of Oncology, Royal North Shore Hospital, St Leonards 2065, New South Wales, Australia. Electronic address: nick.pavlakis@sydney.edu.au.
  • Levchenko E; Petrov Scientific Research Oncology Institute, St. Petersburg 197758, Russia. Electronic address: maurice.perol@lyon.unicancer.fr.
  • Platania M; Fondazione IRCCS, 20133 Milan, Italy. Electronic address: marco.platania@istitutotumori.mi.it.
  • Oliveira J; Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal. Electronic address: julio.oliveira@ipoporto.min-saude.pt.
  • Novello S; Department of Oncology, University of Turin, 10126 Turin, Italy. Electronic address: silvia.novello@unito.it.
  • Chiari R; Hospital of Perugia, Santa Maria della Misericordia, 06129 Perugia, Italy. Electronic address: ritachiari@libero.it.
  • Moran T; Department of Medical Oncology, Catalan Institute of Oncology-Badalona, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona (UAB), Badalona Applied Research Group in Oncology (B-ARGO), 08916 Badalona, Barcelona, Spain. Electronic address: mmoran@iconcologia.net.
  • Mitry E; F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland. Electronic address: e.mitry@me.com.
  • Nüesch E; F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland. Electronic address: eveline.nueesch.en1@roche.com.
  • Liu T; F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland. Electronic address: ting.liu.tl3@roche.com.
  • Balas B; F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland. Electronic address: bogdana_ioana.balas@roche.com.
  • Konopa K; Department of Oncology and Radiotherapy, Medical University of Gdansk, 80-001 Gdansk, Poland. Electronic address: konopa@gumed.edu.pl.
  • Peters S; Lausanne University Hospital, 1011 Lausanne, Switzerland. Electronic address: Solange.Peters@chuv.ch.
Lung Cancer ; 138: 79-87, 2019 12.
Article en En | MEDLINE | ID: mdl-31654838
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma de Pulmón de Células no Pequeñas / Medición de Resultados Informados por el Paciente / Quinasa de Linfoma Anaplásico / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Prognostic_studies Aspecto: Patient_preference Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Lung Cancer Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article Pais de publicación: Irlanda
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma de Pulmón de Células no Pequeñas / Medición de Resultados Informados por el Paciente / Quinasa de Linfoma Anaplásico / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Prognostic_studies Aspecto: Patient_preference Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Lung Cancer Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article Pais de publicación: Irlanda